Product Information
EXEMESTANE 25 MG TABLET is a generic product labeled by Breckenridge Pharmaceutical Inc., priced at $0.7478 per EA under NDC 51991000590. Its NADAC has been published 274 times since Jul 7, 2021.
FDA first approved this application on Feb 21, 2019. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
25 mg/1
Manufacturer
Breckenridge Pharmaceutical Inc.NDC
51991000590
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
EXEMESTANEApproval Type
Generic (ANDA)
FDA Application
ANDA211031FDA Approved
2/21/2019
TE Code
AB
On Market Since
12/19/2019
Pharmacological Classes
Price Statistics
The NADAC for EXEMESTANE 25 MG TABLET has been published 274 times since Jul 7, 2021, and over the history we have for it it has declined 55.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.7478 per EA |
|---|---|
| All-time high | $1.8650 (Nov 10, 2021) |
| All-time low | $0.5602 (Jul 17, 2024) |
| 52-week high | $0.7478 |
| 52-week low | $0.5751 |
| Median price | $0.8666 |
| Average price | $0.9309 |
| Largest weekly change | +39.9% (Jan 18, 2023) |
| Weeks tracked | 274 |
| Tracking since | Jul 7, 2021 |
Generic Alternatives
The matcher finds 6 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Breckenridge Pharmaceutical Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Exemestane market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Aromatase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of EXEMESTANE 25 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for EXEMESTANE 25 MG TABLET, manufactured by Breckenridge Pharmaceutical Inc., is $0.7478 per EA (NDC 51991000590), effective Sep 30, 2026.
How has the price of EXEMESTANE 25 MG TABLET changed over time?
Over the history we have for it, the NADAC for EXEMESTANE 25 MG TABLET has declined 55.4%. It has been tracked across 274 weekly CMS publications since Jul 7, 2021.
What are the highest and lowest recorded NADAC prices for EXEMESTANE 25 MG TABLET?
Since Jul 7, 2021, the NADAC for EXEMESTANE 25 MG TABLET has ranged from a low of $0.5602 (Jul 17, 2024) to a high of $1.8650 (Nov 10, 2021), with a median of $0.8666 per EA.
Are there cheaper alternatives to EXEMESTANE 25 MG TABLET?
6 manufacturers publish a NADAC-priced product with the same active ingredient and strength as EXEMESTANE 25 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures EXEMESTANE 25 MG TABLET?
EXEMESTANE 25 MG TABLET (NDC 51991000590) is labeled by Breckenridge Pharmaceutical Inc., and CMS classifies it as a generic product.